A Retrospective Assessment of Topiramate in Children and Adolescents with Pervasive Developmental Disorders
The DOI matches its OpenAlex record.
Abstract
An open-label retrospective study was conducted to assess the effectiveness and tolerability of topiramate in children and adolescents with pervasive developmental disorders (PDD). Topiramate is a novel antiepileptic drug approved as an adjunctive treatment for seizure disorders. A retrospective chart review was conducted in an outpatient clinic specialized in treating individuals with developmental disabilities, to identify all children and adolescents with PDD who received topiramate. Patients were included if concomitant medications remained unchanged. Treatment response was assessed using the Global Improvement item of the Clinical Global Impressions scale (CGI-GI), based on a review of medical records and the Conners Parent Scale (CPS), as completed by parents. Fifteen patients were identified (12 male, 3 female; age = 14.7 +/- 3.3 years), including 11 patients with autistic disorder, 2 patients with Asperger's disorder, and 2 patients with PDD not otherwise specified (PDD, NOS). Eight patients (4 patients with autistic disorder, 2 patients with Asperger's disorder, and 2 patients with PDD, NOS) were judged to be responders, as defined by a score of 1 or 2 on the CGI-GI. Treatment duration was 25 +/- 16 weeks, and the mean dose was 235 +/- 88 mg. Differences between baseline and the end-of-trial period were observed in the following CPS subscales: conduct, hyperactivity, and inattention. No differences were noted in the psychosomatic, learning, and anxiety subscales. Three patients discontinued topiramate because of side effects, with 2 patients experiencing cognitive difficulties and 1 patient a skin rash. Topiramate may be beneficial for treating secondary symptoms of PDD, and prospective openlabel studies and double-blind, placebo-controlled studies to assess its efficacy and safety are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders
Aman, M. G., Farmer, C. A., Hollway, J., & Arnold, L. E. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.009 · Cited by 82
Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder
Hazell, P. (2007) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2007.00995.x · Cited by 69
Metadata
- Authors
- Hardan, A. Y., Jou, R. J., & Handen, B. L.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- Mary Ann Liebert, Inc.
- Published
- 2004-09-01
- Volume
- 14
- Issue
- 3
- Pages
- 426-432
- ISSN
- 1044-5463 (ISSN-L)
- OpenAlex
- W2062789857
- Cited by
- 50
- References
- 0
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Retrospective Assessment of Topiramate in Children and Adolescents with Pervasive Developmental Disorders. https://app.cochat.ai/papers/10.1089/1044546042389082
- The paper
- Hardan, A. Y., Jou, R. J., & Handen, B. L. (2004). A Retrospective Assessment of Topiramate in Children and Adolescents with Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/1044546042389082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.